Form 4: Intra-Cellular Therapies EVP, Chief Medical Officer Suresh K. Durgam Reports Stock Sales

Suresh K. Durgam, EVP and Chief Medical Officer of Intra-Cellular Therapies, Inc., reports the sale of common stock and conversion of restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 23, 2024, Suresh K. Durgam converted 7,907 restricted stock units into common stock.
• Between February 26, 2024, Suresh K. Durgam sold 1,400 shares of common stock at a weighted average price of $69.38, 1,400 shares at $70.16, and 1,312 shares at $71.02.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 13, 2023.
• The reporting person will use a majority of the proceeds from these sales to cover tax liabilities arising from the vesting of restricted stock units.
• Following these transactions, Suresh K. Durgam directly owns 9,488 shares of Intra-Cellular Therapies, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing primarily reports stock sales under a pre-arranged trading plan, which is a common practice. The sales are partly to cover tax obligations, further neutralizing the sentiment.

Industry Context

Form 4 filings are a routine part of the financial markets, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about a company's prospects, although sales under pre-arranged trading plans are generally less informative than discretionary trades.

Stakeholder Impact

• The stock sales by an executive could be perceived negatively by some shareholders, although the existence of a pre-arranged trading plan mitigates this concern.
• The use of proceeds to cover tax liabilities is a standard practice and has no direct impact on other stakeholders.

Key Dates